Acemit

Quick links to important sections

Acemit

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acemit

What is Acemit?

Acemit is a prescription medication whose active ingredient is Acetazolamide, primarily classified as a Carbonic Anhydrase Inhibitor (CAI). Its core purpose is to modulate fluid and pressure balance within the body, which helps alleviate symptoms associated with fluid retention and elevated internal pressure.


Quick Facts

Property Description
Active Ingredient Acetazolamide
Forms Tablet, Extended-Release Capsule, Powder for IV Injection
Pharmacological Class Carbonic Anhydrase Inhibitor (CAI)
General Purpose Regulator of fluid and pressure balance
Origin Synthetic, Sulfonamide derivative

Identity, Composition, and General Purpose

Acemit is chemically defined as a nonbacteriostatic sulfonamide derivative of synthetic origin, belonging to the broader pharmacological category of diuretic agents. The medication is a single-ingredient product containing only the active substance Acetazolamide (C4H6N4O3S2). This drug is fundamental to managing conditions where abnormal fluid distribution or excessive internal pressure, such as elevated intraocular pressure, is a primary concern. The regulatory action performed by the substance promotes the urinary excretion of bicarbonate and has established therapeutic applications in treating fluid imbalance.

How Acemit Works at a Fundamental Level

Acemit functions by specifically inhibiting the Carbonic Anhydrase enzyme, a biological component that is crucial for managing the concentration of bicarbonate ions in several key organs, including the kidneys and eyes.

This enzyme inhibition leads to two central physiological outcomes: in the kidneys, it increases the removal of water and electrolytes, providing the desired diuretic effect for fluid reduction. Concurrently, in the eye, it reduces the rate at which aqueous humor is produced, which directly lowers the fluid pressure inside the eyeball. The ability of Acetazolamide to decrease aqueous humor secretion is the primary mechanism for its use in ocular pressure management.

Regulatory References

  1. National Library of Medicine (MedlinePlus)

What side effects are possible with Acemit?

Possible Side Effects and Safety Information

The safety profile of Acemit, whose active ingredient is Acetazolamide, is defined by regulatory agencies based on categorized adverse reactions and specific usage constraints. Adverse reactions are officially grouped by the systems they affect and their frequency of occurrence.

Frequency and System-Organ Classes

The most frequently reported adverse reaction, classified as Very Common in regulatory documents, is paresthesia (a tingling or 'pins and needles' sensation). Effects classified as Common include polyuria (increased urination), drowsiness, fatigue, and gastrointestinal disturbances such as anorexia (loss of appetite) and taste alteration.

Officially documented adverse effects are grouped into system-organ classes, including Nervous System Disorders, Gastrointestinal Disorders, Metabolism and Nutrition Disorders (e.g., metabolic acidosis and electrolyte imbalance), and Renal and Urinary Disorders.


Serious Adverse Reactions and Safety Constraints

Acemit's chemical structure as a sulfonamide derivative necessitates the regulatory listing of rare but serious risks. These include potentially fatal reactions such as aplastic anemia, agranulocytosis (severe blood disorders), and severe mucocutaneous reactions like Stevens-Johnson Syndrome (SJS).

Regulatory documents define specific contraindications where the medicine should not be used. These include severe cases of hepatic impairment (liver failure), marked renal disease, pre-existing hypokalemia (low potassium levels), and a history of hypersensitivity to sulfonamides. The formation of renal calculi (kidney stones) is a documented risk associated with long-term exposure to the medicine.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Information for Acemit

The substance Acemit is not an approved medicine with an official, standardized regulatory label (such as those from the U.S. FDA or the European Medicines Agency (EMA)) publicly available through authoritative medical or regulatory sources. Therefore, a formally documented overdose profile, including official signs, symptoms, dose-related risks, and required emergency procedures, does not exist in the public regulatory domain for this specific name.


Overdose scope

Documented overdose presentations: No specific, confirmed presentations are available from regulatory labeling. Physiological systems affected (as stated in label): No officially stated affected systems. Dose-related or exposure-related factors (if applicable): No specific overdose dose levels or circumstances are officially published. Population-specific overdose notes (if applicable): No population-specific risks are officially documented. Emergency-response statements (as written in official documents): No explicit emergency actions are included in regulatory labeling. When immediate medical help is required (label-derived phrasing only): No official phrasing is available.


Overdose classifications (high-level)

Severity classification (as defined in official documents): Not officially classified. Regulatory basis (EMA / FDA / etc.): Not found in publicly available official regulatory documents. Overdose-context constraints (as defined in official documents): No constraints are officially defined.


Resulting overdose structure

Official overdose statements:

  • No specific official overdose statements for Acemit are available in standard government regulatory and authoritative medical databases.
  • Given the absence of a defined regulatory label, no official information exists regarding overdosage symptom clusters or required patient management procedures.

Connection to the overall overdose profile (2–4 sentences): The current regulatory landscape does not include an approved drug product named Acemit with an associated official overdose section. Consequently, there is no governmental documentation specifying overdose symptoms, required emergency interventions, or clear guidance on when urgent medical attention is necessary. Any information regarding overdose for this substance would need to be derived from non-regulatory, general toxicological principles.

Therapeutic Uses of Acemit

What Acemit Treats: Main Uses and Benefits

The therapeutic utility of Acemit (Acetazolamide) is applied across domains where additional symptomatic support is needed, particularly in situations involving pressure imbalances and fluid volume management. The medication is considered relevant in conditions presenting with significant symptomatic burden across multiple major organ systems. Acemit is commonly used across conditions presenting with acute or episodic manifestations, including managing certain forms of glaucoma, Idiopathic Intracranial Hypertension (IIH), edema (fluid retention) associated with conditions like Congestive Heart Failure, and as symptomatic support for Acute Mountain Sickness and specific seizure disorders.


High-Pressure and Fluid Control Support

Acemit is used in clinical settings that involve acute or unstable symptom patterns, such as when patients experience symptoms related to heightened physiological activity due to pressure buildup or symptoms related to systemic imbalance from excess fluid. For patients dealing with these recurrent or intense manifestations, “the focus is on easing the symptom load during difficult episodes.” The support provided by Acemit contributes to improved comfort during these periods of heightened symptoms.


Quick Fact: Relief for Pressure-Related Discomfort
Acemit assists in maintaining functional stability by helping address symptoms linked to organ-specific functional stress caused by high internal fluid pressures.

Regulatory References

  1. NIH NCBI Bookshelf summary

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Eligibility for Acemit (Acetazolamide) is strictly defined by regulatory documents based on patient health status and demographics. The medication is contraindicated and must not be used by individuals with known hypersensitivity to Acetazolamide or any sulfonamide derivative. Absolute non-eligibility also applies to patients diagnosed with severe organ dysfunction, specifically marked renal failure and severe hepatic insufficiency (cirrhosis).

Use is further prohibited in cases of key metabolic disorders, such as pre-existing hyperchloremic acidosis, adrenocortical insufficiency, and depressed blood levels of sodium (hyponatremia) or potassium (hypokalemia). These conditions represent formal exclusions listed in official prescribing information.

Restricted and Not-Established Use

While approved for use in adults, the safety and effectiveness for long-term use in the pediatric population have not been established by regulatory bodies. Use during pregnancy is generally not recommended and is restricted to situations where the potential benefit explicitly justifies the potential risk to the fetus (Pregnancy Category C). Caution is also advised for older adults due to the higher prevalence of decreased organ function.

What should I know about interactions with other medicines?

Acemit (Acetazolamide) interacts with several medicinal products through officially documented regulatory pathways. The most severe restriction involves co-administration with high-dose Aspirin (Acetylsalicylic Acid), which is associated with a reported risk of severe systemic toxicity, including metabolic acidosis and potentially coma. Other Carbonic Anhydrase Inhibitors are officially not advised for concurrent use due to possible additive effects.

Pharmacokinetic interactions are documented for several drugs. Acemit modifies the metabolism of Phenytoin, resulting in increased plasma concentrations of the anticonvulsant. Conversely, the gastrointestinal absorption of Primidone is decreased, leading to reduced serum levels. Co-administration may also elevate Cyclosporine blood levels.

Due to Acemit’s influence on urinary pH, the renal excretion of other agents is altered. This leads to reduced excretion and enhanced effect of medicines like Quinidine and Amphetamine, but increased excretion and a decreased effect of Lithium. Co-administration with Sodium Bicarbonate is associated with an increased risk of renal calculus formation.

In specific populations, caution is required for elderly patients with impaired renal function who are predisposed to acid/base imbalances when taking co-administered drugs. The risk of drowsiness or dizziness may be increased when combining Acemit with alcohol.

Mechanism of Action

How Acemit Works: Mechanism of Action

Acemit functions as a multi-target inhibitor that modulates key intracellular signaling pathways governing cellular growth and survival. The mechanism operates at the cellular level by directly influencing proliferative and anti-apoptotic signaling.

Targeting Proliferative Signals via EGFR and STAT3

Acemit's primary molecular action is the inhibition of the Epidermal Growth Factor Receptor (EGFR) and the transcription factor Signal Transducer and Activator of Transcription 3 (STAT3). By blocking the activation of these key regulatory proteins for cellular division, the initial signal for growth is suppressed. The resulting physiological effect is the reduction of cell proliferation and the induction of controlled cell death (apoptosis).

Modulating Downstream Survival and Angiogenesis Pathways

Following primary inhibition, Acemit addresses the molecular cascade by suppressing the activity of downstream survival factors, including AKT and Mitogen-Activated Protein Kinase (MAPK). This action eliminates pro-survival signals within the cell. The physiological consequence is a dual effect: further promoting the apoptotic response and achieving an anti-angiogenic effect, which involves inhibiting the formation of new blood vessels.

Dosage and Administration Information

How Acemit is Used: Official Administration Guidelines

Acemit (Acetazolamide) is administered following standardized protocols to ensure consistent and proper use. This section details the official routes of administration, standard dosing schedules, and essential preparation requirements as established in prescribing information.


Administration Methods and Forms

Acemit is available as Immediate-Release (IR) tablets (125 mg, 250 mg) and Extended-Release (ER) capsules (500 mg) for oral administration. The medication is also available as a 500 mg powder for intravenous (IV) injection for use in acute situations or when oral intake is not feasible. The intramuscular (IM) route is not recommended.

Standard Dosing and Frequency

Use Case Standard Adult Regimen Key Frequency/Pattern
Chronic Glaucoma 250 mg to 1,000 mg daily Divided doses for amounts over 250 mg
Edema (Diuresis) 250 mg to 375 mg once daily Intermittent/Cyclic (e.g., 1-2 days on, 1 day off)
Acute Glaucoma Initial 500 mg, then 125 mg to 250 mg Short-term, often every 4 hours
Acute Mountain Sickness 500 mg to 1,000 mg daily Initiated 24–48 hours before ascent

Oral forms may be taken with or without food.


Preparation and Special Use Instructions

For the IV injection, the 500 mg powder must be reconstituted with at least 5 mL of Sterile Water for Injection before use. Extended-Release capsules must be swallowed whole and must not be crushed or chewed.

Population Adjustments

Dosing requires adjustment in patients with renal impairment. If Creatinine Clearance (CrCl) is 10-50 mL/min, administration should be reduced or given no more frequently than every 12 hours.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Acemit

This overview summarizes the research evidence describing the medicine's clinical evaluation from authoritative governmental and peer-reviewed sources. The research landscape for Acemit includes historical clinical observation, controlled trials, and contemporary systematic reviews. Research for this medicine has been applied in studies examining patient-reported experiences relevant in trials assessing short-term or episodic symptom patterns across several conditions.


Study Designs for Glaucoma and Idiopathic Intracranial Hypertension (IIH)

Early evidence for Glaucoma was established through historical clinical observation and short-term studies, which monitored changes in intraocular pressure (IOP) measured in the observed populations. Research explored the relationship between the medicine's mechanism and measures of aqueous humor production. For IIH, the evidence is supported by dedicated, large-scale Randomized Controlled Trials (RCTs). These studies examined outcomes such as visual field sensitivity and objective measurements of optic nerve swelling (papilledema). Studies reported observations where the group receiving the medicine plus diet/weight management experienced measured change in visual field sensitivity and the severity of papilledema.


Research Evidence for Edema, Altitude Sickness, and Seizure Support

Recent RCTs have explored Acemit as an add-on therapy for fluid retention (edema), typically in hospitalized adults. These studies monitored observations where increased fluid and sodium excretion were measured in the short-term. For Acute Mountain Sickness (AMS), multiple placebo-controlled RCTs reported a difference in the measured incidence of AMS symptoms between participants receiving the medicine and those receiving a placebo. The evidence base for managing seizure disorders is mainly composed of older clinical data and non-controlled observational studies, which reported observations related to the rate of seizure occurrence in specific groups.


Understanding Limitations and Uncertainty

The available evidence often focuses on short-term or acute responses. Long-term effects are not fully established for all indications, and research provides limited insight into long-term changes over many years. Data for certain groups, such as pregnant populations and individuals with pre-existing severe kidney or liver conditions, remain insufficient, and findings reflect the specific conditions and populations under which they were conducted.

Key Studies & References

  1. Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) - A Multicenter, Double-blind, Randomized, Placebo-controlled Study of Weight-Reduction and/or Low Sodium Diet Plus Acetazolamide vs Diet Plus Placebo
  2. Acetazolamide in Decompensated Heart Failure With Volume Overload (ADVOR) Trial: Efficacy of acetazolamide in patients with acute decompensated heart failure

Frequently Asked Questions (FAQ)

Common questions about Acemit (FAQ)


Q: What is the main reason doctors prescribe Acemit?

Official product information states that Acemit is indicated as an adjunctive treatment for specific types of glaucoma, and for the management of edema due to heart failure or certain medications. It is also described for the prevention or amelioration of symptoms associated with acute mountain sickness and as an addition to therapy for certain convulsive disorders.


Q: How quickly should I expect to notice anything after starting Acemit?

Regulatory documents indicate that the immediate-release tablet form of Acemit typically begins its action within 30 minutes to 1 hour after taking it. The medication's concentration in the blood typically peaks within a few hours, with effects generally lasting 8 to 12 hours. Extended-release capsules are designed to provide a more prolonged duration of action.


Q: Is Acemit known to affect mood or energy levels?

Official information indicates that Acemit may cause fatigue and drowsiness (somnolence) as documented adverse reactions. Other less common neurological effects that have been reported include depression, excitement, and confusion, which may be experienced as changes in energy levels.


Q: What does it mean that Acemit 'works on the central nervous system' (CNS)?

Acemit functions by inhibiting the carbonic anhydrase enzyme throughout the body, including in the central nervous system (CNS). This action is thought to affect abnormal electrical discharge from nerve cells in the brain, which is the mechanism relevant to its official use as an additional treatment for certain convulsive disorders.


Q: Is Acemit a type of opioid or controlled substance?

Acemit is classified as a carbonic anhydrase inhibitor and a sulfonamide derivative. Regulatory agencies that manage drug classifications, such as the U.S. Drug Enforcement Administration (DEA), do not list Acetazolamide as a controlled substance.


Q: Can Acemit affect my sleep schedule?

The official product information lists drowsiness as a common side effect, which has the potential to influence sleep patterns and alertness. In the context of acute mountain sickness, the drug is sometimes noted for helping with sleeping difficulty associated with the condition.


Q: Is it normal to feel a little dizzy when first starting Acemit?

Official labeling documents confirm that dizziness is a documented neurological adverse reaction associated with Acemit. This information is noted in the drug's safety profile.


Q: Is Acemit safe for older adults to use?

Regulatory documentation advises caution for older adults. Due to the common age-related decline in kidney function, older adults may be more susceptible to higher concentrations of the drug in their blood. Caution is advised, and administration may require dosage adjustments and monitoring.


Q: Is Acemit excreted in breast milk?

Studies reviewed by health organizations indicate that the active ingredient, Acetazolamide, is excreted into breast milk, but typically at low concentrations. Professional medical guidelines often describe the use of carbonic anhydrase inhibitors as compatible with breastfeeding.


Q: What is the difference between Acemit and a generic version of the drug?

Acemit is the brand name assigned to the drug whose active ingredient is Acetazolamide. The generic version contains the same active medicinal substance and is expected to work in the same way, but it may contain different inactive ingredients (fillers, dyes, etc.) than the brand-name product.


Q: Is it okay to crush or break Acemit tablets?

Official instructions specify that the extended-release capsules must be swallowed whole and must not be crushed or chewed to prevent an unsafe, rapid release of the medicine. Official prescribing information contains specific instructions for the use of immediate-release tablets.


Q: Can I take Acemit if I have a history of seizures?

Acemit (Acetazolamide) is officially listed as an adjunctive treatment for certain convulsive disorders (epilepsy). A history of seizures is not formally listed as a contraindication in regulatory documents.


Q: How long is Acemit typically prescribed for?

The required duration of treatment varies widely depending on the condition being addressed. Official dosing information reflects that Acemit is used for both short-term situations, like acute mountain sickness, and for long-term management, such as in chronic simple glaucoma.


Q: What kind of monitoring is needed while taking Acemit?

Regulatory documents mention the need for periodic monitoring while taking Acemit. Due to potential risks like severe blood disorders and electrolyte imbalance, the periodic monitoring of blood cell counts and serum electrolytes is recommended, especially when beginning therapy.


Q: Is it true that Acemit can affect my driving ability?

Official warnings describe that Acemit may impair a person's mental and physical abilities. Because the medication can cause drowsiness, it may affect the performance of tasks that require alertness and concentration, such as operating machinery or driving a motor vehicle.


Q: How is Acemit eliminated from the body?

The official product information, specifically the clinical pharmacology sections, describes that Acemit is primarily eliminated from the body unchanged. The main pathway for this elimination is through the kidneys via renal excretion.


Q: What is the half-life of Acemit?

Regulatory data on the pharmacokinetics of Acemit (Acetazolamide) indicates that its plasma half-life generally ranges from approximately 2.4 to 5.8 hours in the body.


Q: Does Acemit cause dry mouth?

Official regulatory documents list dry mouth as a documented adverse reaction that affects the gastrointestinal system and may occur with the use of Acemit.


Q: What are the potential risks of taking too much Acemit?

Overdosage is a documented risk that can lead to severe metabolic acidosis and significant electrolyte imbalances, such as low potassium (hypokalemia). Overdosage can also result in central nervous system effects, including drowsiness, confusion, and potential seizures, requiring immediate medical intervention.


Q: Can Acemit affect blood sugar levels?

Official regulatory documents state that caution should be exercised when using Acemit in patients with diabetes mellitus. The labeling notes that the drug has the potential to interfere with blood sugar control and, in rare instances, may cause high blood sugar (hyperglycemia) or the presence of glucose in the urine (glycosuria).


Q: Is Acemit a maintenance drug or a short-term treatment?

Acemit is utilized in both ways depending on the condition. For some conditions, like acute mountain sickness, it is used for a short-term period. For other conditions, such as certain types of chronic glaucoma, it may be used for maintenance or long-term management.

How should Acemit be stored and disposed of?

Storage and Disposal Requirements for Acemit

Storage conditions for Acemit (acetazolamide) differ by formulation to ensure stability, and all product must be kept out of the sight and reach of children.


Storage Requirements

  • Oral Forms (Tablets/Capsules): Store at Controlled Room Temperature (20 to 25 C), protected from light and moisture in the original container.
  • Injection (Powder): The unreconstituted powder is stored at 20 to 25 C.
  • Reconstituted Solution: This solution must be refrigerated (2 to 8 C) and is stable for 3 days. If stored at room temperature, it must be used within 12 hours.

Disposal

Do not dispose of Acemit via wastewater or household trash. Unused or expired product must be discarded in accordance with local waste disposal requirements, such as through a drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Acemit found in:

A-Z Index: